Literature DB >> 10993580

Energy expenditure in Alzheimer's disease.

E T Poehlman1, R V Dvorak.   

Abstract

Alzheimer's disease type dementia is a growing health problem and is one of the leading causes of death among elderly people. Unexplained weight loss and cachexia is a frequent clinical finding in patients with Alzheimer's disease. It has been postulated that Alzheimer's disease may by characterized by dysfunction in body weight regulation. This brief review examines energy intake, energy expenditure and body composition in Alzheimer's disease. We consider whether inappropriately high levels of energy expenditure may contribute to unexplained weight loss and decline in nutritional status. Specifically, we will consider studies that have examined body composition, daily energy expenditure and its components. The application of doubly labeled water and indirect calorimetry to problems of "wasting" has increased our knowledge regarding energy expenditure and physical activity levels in Alzheimer's patients. Although the number of studies are limited, results do not support the notion that a "hypermetabolic" state contributes to unexplained weight loss in Alzheimer's disease, even in cachectic patients. Clinical strategies aimed at developing feeding strategies to maintain adequate caloric intake and the restoration of energy balance should be a future area of investigation in Alzheimer's research.

Entities:  

Mesh:

Year:  1998        PMID: 10993580

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  7 in total

1.  Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging.

Authors:  Alexandra M V Wennberg; Deborah Gustafson; Clinton E Hagen; Rosebud O Roberts; David Knopman; Clifford Jack; Ronald C Petersen; Michelle M Mielke
Journal:  J Alzheimers Dis       Date:  2016-05-04       Impact factor: 4.472

2.  Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease.

Authors:  Antonio L Teixeira; Breno S Diniz; Alline C Campos; Aline S Miranda; Natalia P Rocha; Leda L Talib; Wagner F Gattaz; Orestes V Forlenza
Journal:  Neuromolecular Med       Date:  2012-09-28       Impact factor: 3.843

Review 3.  Energy expenditure and aging.

Authors:  Todd M Manini
Journal:  Ageing Res Rev       Date:  2009-08-19       Impact factor: 10.895

4.  Targeted Metabolomic Analysis in Alzheimer's Disease Plasma and Brain Tissue in Non-Hispanic Whites.

Authors:  Karel Kalecký; Dwight C German; Albert A Montillo; Teodoro Bottiglieri
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 5.  Adiponectin as a new paradigm for approaching Alzheimer's disease.

Authors:  Juhyun Song; Jong Eun Lee
Journal:  Anat Cell Biol       Date:  2013-12-24

Review 6.  Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease.

Authors:  Steven N Austad; Scott Ballinger; Thomas W Buford; Christy S Carter; Daniel L Smith; Victor Darley-Usmar; Jianhua Zhang
Journal:  Acta Pharm Sin B       Date:  2021-06-30       Impact factor: 11.413

7.  Specific suppression of insulin sensitivity in growth hormone receptor gene-disrupted (GHR-KO) mice attenuates phenotypic features of slow aging.

Authors:  Oge Arum; Ravneet K Boparai; Jamal K Saleh; Feiya Wang; Angela L Dirks; Jeremy G Turner; John J Kopchick; Jun-Li Liu; Romesh K Khardori; Andrzej Bartke
Journal:  Aging Cell       Date:  2014-09-20       Impact factor: 9.304

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.